{"tid":2374248,"cid":5,"subCid":0,"title":"南韓SK與美國藥廠洽商新冠疫苗技術轉讓　在韓生產","createTime":"2021-01-21T05:43:47.000Z","updateTime":"2021-01-21T05:47:25.000Z","uid":113000,"like":0,"dislike":0,"uniUserReply":2,"replies":[{"pid":"921fd947dd53cd8b6fca7e0f7683cfbf0fd9e2a5","tid":2374248,"uid":113000,"like":0,"dislike":0,"score":0,"citedBy":0,"replyTime":"2021-01-21T05:43:47.000Z","msg":"南韓企業SK生物科學正與美國諾瓦瓦克斯醫藥公司(NVAX)，洽商新型冠狀病毒疫苗技術轉讓協議，以在韓生產足夠2000萬人注射的新冠疫苗。南韓總統文在寅今日前往慶尚北道安東市的SK生物科學工廠視察，指隨著SK與諾瓦瓦克斯簽訂協議，可確保全國有合共7600萬劑疫苗供應。另外，他指SK生物科技正致力於自主研發國產疫苗，有望明年面世。<br />\n<br />\n文在寅又表示，政府計劃下月啟動疫苗接種工作，最遲11月前形成群體免疫力。政府並將制定針對接種疫苗後出現不良反應的處理和賠償方案。<br />\n<br />\n<a href=\"https://www.881903.com/news/amp/international/2375568\" data-sr-url=\"https://r.lihkg.com/link?u=https%3A%2F%2Fwww.881903.com%2Fnews%2Famp%2Finternational%2F2375568&d=PT6dGXJ5JuBAxmbDRmxpcPcKxKGkGiqypQ%2FDN8PQntA%3D&h=dcb1fa3e\" data-auto-link target=\"_blank\">https://www.881903.com/news/amp/international/2375568</a>"},{"pid":"e4319fee45005b8c484aa3de633427caf56237e2","tid":2374248,"uid":14918,"like":1,"dislike":0,"score":1,"citedBy":0,"replyTime":"2021-01-21T05:47:25.000Z","msg":"SK連流感針都死人 搞到比外國ban<br />\n專做ram啦<img src=\"/assets/faces/normal/adore.gif\" class=\"hkgmoji\" />"}]}